ascendis transcon glp-1 program Novo Nordisk signs $285M deal with Danish neighbor Ascendis Pharma and Novo Nordisk

Balakrishnan SD, Anuradha CV

doi: 10.1074/jbc.M112.390997

Results clearly showed that the tyrosine-nitration level was reduced in proportion to the molar ratios of GSSSG and LASSS relative to HGF, as revealed by the decrease in anti-nitroY mAb-positive HGF (60-kDa -chain and 90-kDa proform) normalized to total HGF -chain as a loading control, that was monitored by stripping with SDS-ME solution and re-probing the blot with anti-HGF -chain N-terminal domain mAb (Figure 1b,c, second and third rows)

Taken together, these results indicate that OsDHAR has potent chaperone-like properties and is capable of protecting proteins from precipitation and heat-induced loss of enzymatic activity, suggesting that OsDHAR is a potent inhibitor of stress-induced protein aggregation

Research in mice that are genetically prone to obesity indicates that AOD9604 most likely does not work only by affecting the beta-3-adrenergic receptors found on white fat